Objective: To systematically evaluate the efficacy and safety of cyclophosphamide combined with glucocorticoid in the treatment of Henoch-Schönlein purpura nephritis. Methods: PubMed

EMBase

the Cochrane Library

CBM

CNKI

Wanfang database and VIP database were retrieved to collect the randomized controlled trial of cyclophosphamide combined with glucocorticoid in the treatment of Henoch-Schönlein purpura nephritis. The retrieval time was from the establishment of the database to Oct. 2018. Literature were independently screened by two investigators based on inclusion and exclusion criteria. Data were extracted and literature quality was evaluated according to the Cochrane systematic review method. Meta-analysis was performed by using RevMan 5.3 software. Results: Fifteen clinical studies with a total of 638 children were included. The results of the Meta-analysis showed that compared with the hormone group alone

the cyclophosphamide combined glucocorticoid group had advantages in overall remission rate

24 h urine protein level

serum albumin level and blood creatinine level (P<0.05)

and reducing side effects (P<0.01)

but increasing the risk of gastrointestinal reactions and leukopenia (P<0.05). There was no significant difference between two groups in the incidence of respiratory tract infection

elevated blood pressure and liver dysfunction (P>0.05). Conclusion: Based on the available evidence

cyclophosphamide combined with glucocorticoids in the treatment of children with Henoch-Schönlein purpura nephritis is effective and safe.